bioXXmed AG (FRA:T5O0)

bioXXmed AG Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	0	0.02	0.01	0.04	0.04
Revenue Growth (YoY)	-79.93%	42.27%	-72.59%	23.96%	-0.50%
Gross Profit	0	0.02	0.01	0.04	0.04
Selling, General & Admin	0.01	0.01	0	0.55	0.78
Other Operating Expenses	0.86	0.82	0.83	1.01	1.08
Operating Expenses	0.88	0.82	0.84	1.61	1.87
Operating Income	-0.87	-0.81	-0.82	-1.57	-1.84
Interest Expense	-	-	-0.04	-0	-0
Interest & Investment Income	-	0.02	0.03	0	0
Other Non Operating Income (Expenses)	0	-	-	-	-
EBT Excluding Unusual Items	-0.87	-0.79	-0.83	-1.57	-1.84
Gain (Loss) on Sale of Investments	-0.13	-20.16	-	-2.49	-
Pretax Income	-1	-20.95	-0.83	-4.06	-1.84
Net Income	-1	-20.95	-0.83	-4.06	-1.84
Net Income to Common	-1	-20.95	-0.83	-4.06	-1.84
Shares Outstanding (Basic)	1	1	1	0	0
Shares Outstanding (Diluted)	1	1	1	0	0
Shares Change (YoY)	164.59%	-	27.54%	-	15.39%
EPS (Basic)	-0.73	-40.78	-1.62	-10.08	-4.57
EPS (Diluted)	-0.73	-40.78	-1.62	-10.08	-4.57
Free Cash Flow	-0.92	-0.73	-0.91	-	-1.66
Free Cash Flow Per Share	-0.67	-1.42	-1.78	-	-4.12
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-24950.87%	-4633.08%	-6727.67%	-3516.49%	-5107.18%
Profit Margin	-28540.14%	-120369.63%	-6783.58%	-9095.43%	-5108.88%
Free Cash Flow Margin	-26223.88%	-4194.44%	-7473.42%	-	-4613.89%
EBITDA	-0.79	-0.8	-0.82	-1.55	-1.82
D&A For EBITDA	0.09	0.01	0.01	0.02	0.02
EBIT	-0.87	-0.81	-0.82	-1.57	-1.84

Source: S&P Global Market Intelligence. Standard template. Financial Sources.